Showing results (91-100 of 696) with videos related to
Sort By:
Pageof 70
The American Journal of Medicine|January 3, 2022
Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021Peter Rossing, Murray EpsteinProteomics|August 15, 2013
Improving peptide relative quantification in MALDI-TOF MS for biomarker assessmentAmaya Albalat, Angelique Stalmach, Vasiliki Bitsika, et al.Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.Kidney International. Supplement|March 2, 2011
Need for better diabetes treatment for improved renal outcomePeter Rossing, Dick de ZeeuwNature Reviews. Nephrology|December 10, 2014
Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathyHans-Henrik Parving, Peter RossingDiabetes, Obesity & Metabolism|July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trialOfri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.Free Radical Research|May 12, 2023
Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trialsEmil List Larsen, Andreas Andersen, Laura K Kjær, et al.International Journal of Nephrology|March 13, 2023
The Growing Challenge of Chronic Kidney Disease: An Overview of Current KnowledgeRikke Borg, Nicholas Carlson, Jens Søndergaard, et al.BMJ Open|June 6, 2023
Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study)Marie Møller, Rikke Borg, Iain Bressendorff, et al.Diabetes Care|January 19, 2023
Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover TrialViktor Rotbain Curovic, Niels Jongs, Marjolein Y A M Kroonen, et al.Pageof 70